On September 12, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Kineta, SEP 12, 2022, View Source;utm_medium=rss&utm_campaign=kineta-announces-participation-in-the-h-c-wainwright-24th-annual-global-healthcare-conference [SID1234619422]). The conference is being held as a hybrid event on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Shawn Iadonato, Ph.D., Kineta’s Chief Executive Officer, will provide a corporate update and overview of KVA12.1, Kineta’s IND-ready VISTA blocking immunotherapy that is scheduled to initiate a Phase 1 clinical trial in the fourth quarter of 2022.
Event: H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
Date: September 12-14, 2022
Time: 7:00 A.M. Eastern Time
Location: Virtual webcast to start on-demand on September 12, 2022 at 7:00 A.M. Eastern Time
Participants may access the webcast of the event through the following link:
The webcast can also be accessed in the Investors section of the Kineta website at www.kinetabio.com. The webcast replay will be available shortly after the conclusion of the event for 30 days.